Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2019 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
INMB on Nasdaq
Shares outstanding
27,969,231
Price per share
$1.63
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
5,083,640
Total reported value
$7,930,834
% of total 13F portfolios
0%
Share change
+454,027
Value change
+$653,755
Number of holders
73
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
HIGHBRIDGE CAPITAL MANAGEMENT LLC 5.2% $3,359,664 1,454,400 Highbridge Capital Management, LLC 30 Jun 2025
CVI Investments, Inc. 4.9% -10% $3,225,404 -$239,596 1,396,279 -6.9% CVI Investments, Inc. 30 Jun 2025
Praetorian PR LLC 3.4% -54% $2,127,972 -$1,700,160 921,200 -44% Kupperman Harris 30 Jun 2025

As of 31 Dec 2025, 73 institutional investors reported holding 5,083,640 shares of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB). This represents 18% of the company’s total 27,969,231 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) together control 17% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 4.3% 1,212,100 +2.1% 0% $1,890,877
VANGUARD GROUP INC 3.4% 957,846 +9.3% 0% $1,494,240
GEODE CAPITAL MANAGEMENT, LLC 1.6% 441,650 -5.9% 0% $689,170
STATE STREET CORP 1.2% 347,259 +22% 0% $541,724
Dauntless Investment Group, LLC 1.1% 304,922 1.9% $475,678
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.9% 250,910 +60% 0% $391,419
RAYMOND JAMES FINANCIAL INC 0.75% 210,678 -22% 0% $328,658
NORTHERN TRUST CORP 0.63% 175,649 -7.1% 0% $274,012
MORGAN STANLEY 0.44% 122,512 +62% 0% $191,120
Westside Investment Management, Inc. 0.39% 108,950 +5.3% 0.03% $169,962
XTX Topco Ltd 0.25% 68,865 +41% 0% $107,429
UBS Group AG 0.22% 60,803 -61% 0% $94,852
Bank of New York Mellon Corp 0.21% 58,521 -2.2% 0% $91,293
GOLDMAN SACHS GROUP INC 0.2% 56,477 +269% 0% $88,104
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.18% 50,252 +20% 0% $78,393
Laird Norton Wetherby Trust Company, LLC 0.16% 45,000 +80% 0% $70,200
Jain Global LLC 0.15% 42,051 0% $65,600
JPMORGAN CHASE & CO 0.15% 41,365 -28% 0% $64,530
Focus Partners Advisor Solutions, LLC 0.15% 41,097 +0.36% 0% $64,111
PNC Financial Services Group, Inc. 0.14% 37,805 -1.5% 0% $58,976
BARCLAYS PLC 0.11% 32,018 +6.7% 0% $49,949
RHUMBLINE ADVISERS 0.1% 27,527 +22% 0% $42,935
BANK OF MONTREAL /CAN/ 0.09% 25,987 0% $40,540
TWO SIGMA SECURITIES, LLC 0.09% 25,363 0.01% $39,566
WELLS FARGO & COMPANY/MN 0.09% 24,857 +79% 0% $38,777

Institutional Holders of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 5,083,640 $7,930,834 +$653,755 $1.56 73
2025 Q3 4,655,922 $9,636,676 -$1,934,721 $2.07 73
2025 Q2 5,623,690 $12,725,267 -$10,010,248 $2.31 78
2025 Q1 6,162,475 $48,114,521 -$163,536 $7.81 81
2024 Q4 6,324,914 $29,538,643 +$2,163,001 $4.67 72
2024 Q3 5,352,153 $28,834,750 +$6,030,346 $5.39 65
2024 Q2 4,566,933 $40,279,815 +$15,412,868 $8.82 56
2024 Q1 2,738,821 $32,179,382 +$5,308,168 $11.75 50
2023 Q4 2,292,004 $25,807,938 +$1,854,241 $11.26 47
2023 Q3 2,133,529 $14,477,326 -$5,887,298 $6.77 36
2023 Q2 2,186,070 $24,850,986 +$8,529,775 $9.08 32
2023 Q1 1,804,387 $11,657,371 +$1,101,433 $6.46 33
2022 Q4 1,645,407 $10,430,707 -$728,047 $6.34 32
2022 Q3 1,912,551 $11,855,780 -$744,186 $6.20 32
2022 Q2 2,010,894 $17,633,536 -$2,412,787 $8.84 34
2022 Q1 2,294,234 $19,315,368 -$2,106,118 $8.42 32
2021 Q4 2,484,556 $25,343,080 +$4,757,601 $10.20 42
2021 Q3 1,942,445 $37,703,608 +$4,889,864 $19.42 40
2021 Q2 1,710,752 $30,053,028 +$8,038,213 $17.57 39
2021 Q1 1,305,763 $15,492,692 +$5,444,483 $11.88 32
2020 Q4 793,136 $13,655,776 +$1,189,170 $17.21 25
2020 Q3 992,741 $10,252,248 +$6,463,618 $10.30 27
2020 Q2 358,561 $1,881,000 +$104,639 $5.17 11
2020 Q1 342,213 $1,139,000 +$200,616 $3.32 9
2019 Q4 282,367 $1,637,000 +$40,401 $5.80 9
2019 Q3 274,538 $1,620,000 +$1,390,869 $5.90 9
2019 Q2 38,466 $373,000 -$43,981 $9.72 7
2019 Q1 45,117 $352,000 +$352,000 $7.44 5